1. Dolezal O, Dwyer MG, Horakova D, Havrdova E, Minagar A, Balachandran S, Bergsland N, Seidl Z, Vaneckova M, Fritz D, Krasensky J, Zivadinov R: Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. Int Rev Neurobiol. 2007; 79: 475-89 (IF 1,318).
  2. Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry 2008; 79(4): 407-14 (IF 4,622).
  3. Vaněčková M, Seidl Z. Roztroušená skleróza mozkomíšní a magnetická rezonance: současnost a nové trendy. Čes a Slov Neurol Neurochir 2008; 71/104(6): 664-672. (IF 0,319).
  4. Burgetova A, Seidl Z, Vaneckova M, Jakoubkova M. Concurrent occurrence of multiple sclerosis and primary CNS lymphoma: a case report. Neuro Endocrinol Lett. 2008 29(6): 867-870 (IF 1,359).
  5. Vaneckova M, Seidl Z, Krasensky J, Havrdova E, Horakova D, Dolezal O, Burgetova A, Masek M. Patients’ stratification and correlation of brain MRI parameters to disability progression in multiple sclerosis. European Neurology 2009; 61(5):278-84. (IF 1,424).
  6. Horakova D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, Rimes B, Seidl Z, Vaneckova M, Zivadinov R. Gray matter atrophy and disability progression in patients with early relapsing-g multiple sclerosis. A 5-year longitudinal study. J Neurol Sci. 2009 Jul 15;282(1-2):112-9 (IF2,324).
  7. Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler. 2009 Aug;15(8):965-76 (3,279)
  8. Burgetova A, Seidl Z, Krasensky J, Horakova D, Vaneckova M. Multiple sclerosis and the accumulation of iron in the Basal Ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry. Eur Neurol. 2010;63(3):136-43 (1,494). (studentka PhD)
  9. Vaněčková M, Seidl Z, Krásenský J, Horáková D, Havrdová E, Němcová J, DanešJ Naše zkušenosti sMR monitorací pacientů s roztroušenou sklerózou vklinické praxi Čes Slov Neurol N 2010; 73/106(6): 716-720 (IF 0,246).
  10. Horakova D, Kyr M, Havrdova E, Dolezal O, Lelkova P, Pospisilova L, Bergsland N, Dwyer MG, Hussein S, Seidl Z, Vaneckova M, Zivadinov R.Apolipoprotein E ε4-Positive Multiple Sclerosis PatientsDevelop More Gray-Matter and Whole-Brain Atrophy:a 15-year Disease History Model Based on a 4-yearLongitudinal Study. Folia Biologica 2010; 56: 242-251.(IF 0,924)
  11. Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Tamaño-Blanco M,Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z,Lelkova P, Ramanathan M. HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. J Neuroimmunol. J Neuroimmunol. 2011 Jul;236(1-2):76-80. (IF 2,959)
  12. Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E.Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg. 2012 Sep;114(7):940-6. (IF 1,234)
  13. Vaneckova M, Kalincik T,Krasensky J, Horakova D, Havrdova E, Hrebikova T, Seidl Z. Corpus Callosum Atrophy: a Simple Predictor of Multiple Sclerosis Progression (Longitudinal 9-year Study), Eur Neurol2012;68:23-7(IF 1,500)
  14. Horakova D, Kalincik T, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand 2012 Dec;126(6):390-7. (IF 2,474)
  15. Bergsland N, Horakova D, Dwyer MG, Dolezal O, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2012 Sep;33(8):1573-8 (IF 3,167)
  16. Kalincik T, Vaneckova M, Tyblova M, Krasensky J, Seidl Z, Havrdova E, Horakova D. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLOS ONE2012;7(11):e50101. doi: 10.1371/journal.pone.0050101. (IF 3,730)
  17. Zivadinov R, Bergsland N, Dolezal O, Hussein S, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Potts JA, Kalincik T, Havrdová E, Horáková D: Evolution of cortical and thalamus atrophy and disability progression in early RRMS over 5 years. AJNR Am J Neuroradiol 2013; Oct 34(10):1931-9.(IF 3,167)
  18. Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J, Tamano-Blanko M, Badgett D, Tyblova M, Bergsland N, Hussein S, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Dwyrer MG, Zhang M, Yu H, Duan X, Kalincik T. Ramanathan M. Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLOS ONE January 2013, volume 8, Issue 1, e53996. (IF 3,730)
  19. Zivadinov R, Tekwe C, Bergsland N, Dolezal O, Havrdova E, Krasensky J, Dwyer MG, Seidl Z, Ramasamy DP, Vaneckova M, Horakova D. Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 years: A Longitudinal Study. Mult Scler Int. 2013;2013:231345. doi: 10.1155/2013/231345.
  20. Zivadinov R, Havrdova E, Bergsland N, Tyblova M, Hagemeire J, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Carl E, Kalincik T, Horakova D. Thalamic Atrophy Is Associated with Development of Clinical Definite Multiple Sclerosis. Radiology 2013 2013 Sep;268(3):831-841. (IF z r. 2012 6,339)
  21. Kalincik T, Guttmann Ch, Krasensky J, Vaneckova M, Lelkova P, Tyblova M, Seidl Z, De Jager P, Havrdova E, Horakova D. Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. Genes Immun 2013;Jun 14(4):244-8. (IF z r. 2012 3,675)
  22. Weinstock-Guttman B, Horakova D, Zivadinov R, Tamaño-Blanco M, Badgett D,Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M. Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. J Neuroimmunol. 2013 Aug 2. doi:pii: S0165-5728(13)00183-5. (IF z r. 2012 3,033)
  23. Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M. Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry. 2013 Apr 17. (IF z r. 2012 4,924)
  24. Browne RW, Weinstock-Guttman B, Horakova D, Zivadinov R, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M. Apolipoproteins are Associated with New MRI Lesions and Deep Gray Matter Atrophy in Clinically Isolated Syndromes. JNNP 2014, Aug 85(8):859-64.(IF z r. 2012 4,924)
  25. Zivadinov R, Chin J, Horakova D, Bergsland N, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Hagemeier J, Tyblova M, Carl E,Krasensky J, Vaneckova M, Seidl Z, G. Dwyer M, Havrdova E, Ramanathan M. Humoral Responses to Herpesviruses are Associated with Neurodegeneration After a Demyelinating Event: Results from the Multi-Center SET Study. Journal of Neuroimmunology 2014, 273; 58-64. (IF 3,033)
  26. Browne R, Weinstock-Guttman B, Zivadinov R, Horakova D, Bodziak ML, Taman-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, ramasamy D, Hagemeier J, Qu J, Havrdova E, Ramanathan M. Serum lipoprotein composition and vitamin D metabolite levels in clinically

isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology (2014); 143: 424-433. IF 3,984

  1. Uher T, Blahova-Dusankova J, Horakova D, Bergsland N, Tyblova M, Benedict RH, Kalincik T, Ramasamy DP, Seidl Z, Hagermeier J, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.J Neurol. 2014 Sep;261(9):1735-44. IF 3,578
  2. Uher T, Benedict R, Horakova D, Bergsland N,Blahova Dusankova J,Tyblova M,Ramasamy DP,Seidl Z,Vaneckova M,Krasensky J,Havrdova E, Zivadinov R. Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. Journal of the Neurological Sciences (article in press) (IF 2,262)
  3. Uher T; Horakova D; Bergsland N; Tyblova M; Ramasamy DP; Seidl Z; Vaneckova M; Krasensky J; Havrdova E., Zivadinov R. MRI Correlates of Disability Progression in Patients with CIS Over 48 Months NeuroImage: Clinical (article in press)

Abstracts of meetings

  1. Vaneckova M, Seidl Z, Krasensky J, Havrdova E, Horakova D, Dolezal O, Masek M. The predictive ability of magnetic resonance imaging to progression of clinical disability in patients with multiple sclerosis. J Neurol 2007; 254 (suppl 3): III/163
  2. Horakova D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, Rimes B, Krasensky J, Vaneckova M, Zivadinov R: Is magnetic resonance imaging a reliable tool for prediction of disability progression in patients with early relapsing-remitting multiple sclerosis? 5-year longitudinal study. J Neurol 2007;254 (suppl 3):III/14
  3. Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Vaneckova M, Bergsland N, Zivadinov R: Evolution of different MRI measures in patients with active relapsing - remitting multiple sclerosis over 2 and 5 years: a case control study. J Neurol 2007;254 (suppl 3):III/190.
  4. Horáková D, Havrdová E, Doležal O, Seidl Z, Vaněčková M, Cox J, Dwyer M, Bergsland N, Rimes B, Zivadinov R, Čes Slov Neurol N 2007;70/103
  5. Horakova D,Kyr M, Havrdova E, Dolezal O, Pospisilova L, Dwyer MG, Bergsland N, Seidl Z, Stosic M, Cox JL, Vaneckova M, Zivadinov R. ApoE ε4 positive MS patients develop more gray matter and whole brain atrophy. A 4-year longitudinal study using the 15-year disease onset model. Multiple Sclerosis 2008; 14: S29-S293.
  6. Kelemen A, Dwyer M, Horakova D, Vaneckova M, Havrdova E, Zivadinov R. Measurement of gray matter volume is less susceptible to pseudoatrophy effect than of white matter or whole brain volume in patients with multiple sclerosis, results from Avonex-Steroids-Azathioprine combination study. Multiple Sclerosis 2008;14: S29-293.
  7. Krasulova E, Polreich D, Vackova B, Trneny M, Vaneckova M, Seidl Z, Nytrova P, Mareckova H, Horakova D, Havrdova E. High-dose immunoablation with autologous stem cells transplantation in neuromyelitis optica. Neurology 74, March 2, 2010, suppl 2, A172
  8. Biergsland N, Horakova D, Dwyer MG, Ramasamy D, Havrdova E, Seidl Z, Dolezal O, Hussein S, Carl E, Vaneckova M, Zivadinov R. Five-year serial longitudinal study of deep gray matter atrophy in patients with multiple sclerosis. Neurology 74, March 2, 2010, suppl 2, A235
  9. Vaneckova M, Krasensky J, Havrdova E, Horakova D, Seidl Z. On prediction power of MRI for future development of relapse remitting form of multiple sclerosis. Neurology 74, March 2, 2010, suppl 2, A556
  10. Krasensky J, Vaneckova M, Havrdova E, Burgetova A, Horakova D, Seidl Z. Relaxometry- a new MR marker of neurodegeneration in multiple sclerosis? Neurology 74, March 2, 2010, suppl 2, A291
  11. Zivadinov R, Horakova D, Dolezal O, Bergsland N, Hussein S, Durfee J, You X, Seidl Z, Vaneckova M, Krasensky J, Havrdova E. Association between short-term deep grey matter atrophy and disability progression over five years in patients treated with IM interferon beta-1e. Multiple sclerosis 2010;16: S197-352
  12. Tyblova M, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E. Observation study of early intramuscular interferon Beta-1a treatment in high-risk subject after clinicaly isolated syndrome. rationale, design, and baseline patient characteristics. Neurology 2011; 76; suppl 4; A 323
  13. Dolezal O, Passanese J, Zivadinov R, Horakova D, Dwyer M, Seidl Z, Krasensky J, Vaneckova M, Bergsland N, Havrdova E. Cortical atrophy in males in multiple sclerosis: gender differences in patients with early relapsing remitting multiple sclerosis (RRMS)- magnetic resonance imaging (MRI) longitudinal 5 year follow up study Neurology 2011; 76; suppl 4; A389-390
  14. Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E. Addition of azathioprine and corticosteroids to the interferon therapy reduces long-term clinical progression in multiple sclerosis patients with T2-lesion volume Neurology 2011; 76; suppl 4; A390-391
  15. Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E. Relapse score and brain atrophy predict the response to therapy in individuals with multiple sclerosis. Neurology 2011; 76; suppl 4; A 392
  16. Horakova D, Havrdova E, Dolezal O, Bergsland N, Hussein S, Dwyer M, Durfee J, Seidl Z, Vaneckova M, Krasensky J, Potts J, Zivadinov R. Association between changes in gray matter MRI measures and disability progression over 5 years in patients treated with IM INF b-1a Neurology 2011; 76; suppl 4; A 392
  17. Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Hussein S, Bergsland N, Tamano-Blanco M, Willis L, Tyblova M, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Ramanathan M. HLA DRB1*1501 positivita is associated with increased inflammatory activity and lesion burden at the first demyelinating event. Neurology 2011; 76; suppl 4; A 653-654
  18. Vaneckova M, Krasensky J, Kalincik T, Horakova D, Havrdova E, Seidl Z Comparison of MRI techniques for monitoring of multiple sclerosis(A search for an optimal MRI marker to distinguish future long-term stable patients from the progressing ones). 136th Annual Meeting of the American Neurological Association. Supplements : pp 108.
  19. Vaneckova M, Krasensky J, Kalincik T, Horakova D, Havrdova E, Seidl Z Corpus callosum atrophy – a simple individual predictor of disability in multiple sclerosis. Mult Scler. 2011;17:S391.
  20. Correlation between MRI measures and conversion to clinically definite multiple sclerosis in patients treated with intramuscular interferon Beta – 1a. Horakova D, Kalincik T, Tyblova M, Krasensky J, Vaneckova M, Seidl J, Xiaojun Y, Havrdova E. 64 th Annual meeting of American Academy of Neurology, New Orleans, 21.-28.4. 2012
  21. Subcortical but not cortical gray matter atrophy predicts disability progression over 5 years patients with early relapsing-remitting multiple sclerosis. Zivadinov R, Bergsland N, Dolezal O, Hussein S, Seidl Z, Dwyer M, Vaneckova M, Krasensky J, Potts J, Havrdova E, Horakova D. 64 th Annual meeting of American Academy of Neurology, New Orleans, 21.-28.4. 2012
  22. Higher T2 lesion volume in clinically isolated syndrome indicates higher risk of clinically definite multiple sclerosis. Kalincik T, Vaneckova M, Krasensky J, Seidl Z, Tyblova M, Volna J, Havrdova E, Horakova D. 22nd meeting of European Neurological Society, 9.-12.6.2012, Prague
  23. P. Nytrova, P. Waters, D. Horakova, Y. Hacohen, T. Kalincik, P. Zbornikova, J. Dusankova Blahova, J. Krasensky, M. Vaneckova, E. Havrdova, K.P. Wandinger, A. Vincent: Contactin 2 and contactin-associated protein 2 antibodies in patients with multiple sclerosis and clinically isolated syndrome. Ectrims, Lyon , France 2012
  24. R. Zivadinov, C. Tekwe, N. Bergsland, O. Dolezal, E. Havrdova, J. Krasensky, M. Dwyer, Z. Seidl, D. Ramasamy, M. Vaneckova, D. Horakova : Bi-monthly evolution of cortical atrophy in early relapsing-remitting multiple sclerosis over 2 years. A longitudinal study . Ectrims, Lyon , France 2012
  25. D. Horakova, T. Kalincik, M. Tyblova, J. Krasensky, M. Vaneckova, Z. Seidl, E. Havrdova: Longitudinal follow-up of MRI volumetry in routine clinical practice. Ectrims, Lyon , France 2012
  26. T. Kalincik, M. Vaneckova, M. Tyblova, J. Krasensky, Z. Seidl, E. Havrdova, D. Horakova Relapses influence prognosis in clinically isolated syndrome. Ectrims, Lyon , France 2012
  27. D. Horakova, R. Zivadinov, B. Weinstock-Guttman, E. Havrdova, J. Qu, M. Tamano-Blanco, D. Badgett, M. Tyblova, N. Bergsland, S. Hussein, L. Willis, J. Krasenyk, M. Vaneckova, Z. Seidl, M. Dwyer, X. Duan, T. Kalnicik, M. Ramanathan. Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center Set Study. 65 thAnnual meeting of American Academy of Neurology, San Diego, USA, 2013
  28. R. Zivadinov, E. Havrdova, N. Bergsland, M. Tyblova, J. Hagemeier, Z. Seidl, M. Vaneckova, J. Krasensky, E. Carl, T. Kalincik, D. Horakova. Thalamic Atrophy Is Associated with Development of Clinically Definite MS. 65 thAnnual meeting of American Academy of Neurology, San Diego, USA, 2013
  29. O. Dolezal, T. Gabelic, D. Horakova), N. Bergsland, M. Dwyer, Z. Seidl, J. Krasensky, D. Ramasamy, M. Vaneckova, E. Havrdova, R. Zivadinov: Development of grey matter atrophy in relapsing remitting multiple sclerosis is not gender-dependent: results of a five-year follow-up study 29th Congress of ECTRIMS 18th Congress of RIMS Copenhagen, Denmark / 2 - 5 October, 2013
  30. R. Zivadinov, J. Chin, D. Horakova, N. Bergsland, B. Weinstock-Guttman, M. Tamaño-Blanco, D. Badgett, J. Hagemeier, M. Tyblova, E. Carl, J. Krasensky, M. Vaneckova, Z. Seidl, M. Dwyer, E. Havrdova, M. Ramanathan. Humoral Responses to Herpesviruses are Associated with Neurodegeneration After a Demyelinating Event29th Congress of ECTRIMS 18th Congress of RIMS Copenhagen, Denmark / 2 - 5 October, 2013
  31. B. Weinstock-Guttman, D. Horakova, R. Zivadinov, M. Tamaño-Blanco, D. Badgett, M. Tyblova, M. Vaneckova, Z. Seidl, J. Krasensky, N. Bergsland, D. Ramasamy, J. Hagemeier, E. Havrdova, M. Ramanathan. Interactions of Serum Cholesterol with Anti-herpesvirus Responses Affect Disease Progression in CIS29th Congress of ECTRIMS 18th Congress of RIMS Copenhagen, Denmark / 2 - 5 October, 2013
  32. Horakova D, Kalncik T, Krasensky J, Vaneckova M, Seidl Z, Havrdova E. Corpus Callosum Volume Change in the First Year Is the Strongest Predictor of 9-year Clinical Disability in Multiple Sclerosis, AAN (American academy of neurology) Annual Meeting, 2014, Philadelphia, PA
  33. Uher T, Horakova D, Bergsland N, Tyblova M, Ramasamy DR, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. Development of gray matter atrophy is associated with disability progression in patiens with CIS: A 4 year follow up study. 2014 Joint ACTRIMS-ECTRIMS meeting, Boston, 10-13.9.2014
  34. Uher T, Benedict R, Horakova D, Bergsland N, Dusankova- Blahova J, Tyblova M, Ramasamy DR, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. Preservation of gray matter volume is related to increase of leasing effect on PASAT in CIS patiens on dinase-modifying treatment. 2014 Joint ACTRIMS-ECTRIMS meeting, Boston, 10-13.9.2014
  35. Uher T, Dusankova- Blahova J, Horakova D, Bergsland N, Tyblova M, Benedict R, Kalincik T, Ramasamy DR, Seidl Z, Hagermeire J, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. Longitudinal MRI and neuropsychological assesment of patiens with clinically isolated syndrome 2014 Joint ACTRIMS-ECTRIMS meeting, Boston, 10-13.9.2014
  36. Uher T, Dusankova- Blahova J, Tyblova M, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Horakova D, Relative corpus callosum volume is related to decreased information processing speed in relace-remitting multiple sclerosis patiens. 2014 Joint ACTRIMS-ECTRIMS meeting, Boston, 10-13.9.2014
  37. Uher T, HorakovaD, Kalincik T, Bergsland N, Tyblova M, Ramasamy DR, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. Early MRI predictors of clinical progression over 48 months in CIS patiens treated with Ii.m. interferon beta -1a 2014 Joint ACTRIMS-ECTRIMS meeting, Boston, 10-13.9.2014